Centrus Energy - LEU Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Centrus Energy in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LEU shares.
View LEU analyst ratings or view top-rated stocks.

2 brokerages have issued 12-month price targets for Centrus Energy's stock. Their LEU share price forecasts range from $48.00 to $76.00. On average, they predict the company's stock price to reach $62.00 in the next twelve months. This suggests a possible upside of 50.9% from the stock's current price.
View analysts price targets for LEU or view top-rated stocks among Wall Street analysts.

Centrus Energy's stock was trading at $34.55 at the beginning of 2023. Since then, LEU stock has increased by 19.0% and is now trading at $41.10.
View the best growth stocks for 2023 here.

Centrus Energy saw a decline in short interest in December. As of December 30th, there was short interest totaling 586,200 shares, a decline of 21.9% from the December 15th total of 750,800 shares. Based on an average trading volume of 153,500 shares, the short-interest ratio is currently 3.8 days. Approximately 5.1% of the shares of the company are sold short.
View Centrus Energy's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 8th 2023.
View our LEU earnings forecast.

Centrus Energy Corp. (NYSEAMERICAN:LEU) released its quarterly earnings data on Tuesday, November, 8th. The basic materials company reported ($0.42) EPS for the quarter, missing the consensus estimate of $0.78 by $1.20. The basic materials company earned $33.20 million during the quarter, compared to analysts' expectations of $66.30 million. Centrus Energy had a net margin of 57.33% and a negative trailing twelve-month return on equity of 151.53%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Centrus Energy investors own include Ampio Pharmaceuticals (AMPE), Arbutus Biopharma (ABUS), Aeterna Zentaris (AEZS), Align Technology (ALGN), CTI BioPharma (CTIC), CEL-SCI (CVM), Genocea Biosciences (GNCA), Palatin Technologies (PTN), Vascular Biogenics (VBLT) and Agenus (AGEN).

Centrus Energy trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "LEU."

Centrus Energy's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Sara Bay Financial (2.48%), Dupont Capital Management Corp (0.67%), Allspring Global Investments Holdings LLC (0.02%), Evermay Wealth Management LLC (0.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Daniel B Poneman, Dennis John Scott, John C Dorrian, John M A Donelson, Larry B Cutlip, Morris Bawabeh, Neil S Subin and Philip O Strawbridge.
View institutional ownership trends.

Shares of LEU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LEU stock can currently be purchased for approximately $41.10.

Centrus Energy (NYSEAMERICAN:LEU) has a market capitalization of $597.59 million and generates $298.30 million in revenue each year. The basic materials company earns $175 million in net income (profit) each year or $8.03 on an earnings per share basis.

The company employs 266 workers across the globe.

Centrus Energy's mailing address is 6901 ROCKLEDGE DR SUITE 800, BETHESDA MD, 20817. The official website for the company is www.centrusenergy.com. The basic materials company can be reached via phone at (301) 564-3200, via email at financial@centrusenergy.com, or via fax at 301-564-3201.